Medtech has underperformed pharma by 40% in gross performance this year due to hospital staffing shortages post-COVID and rising input costs that medtech companies (which have fixed hospital contracts) could not pass through, but these comps are now behind us and medtech will significantly outperform pharma for the rest of the year into next year.
causalpending
Speaker
Mike TaylorEvidence Quote
“medtech has underperformed pharma by about 40% spread this year...all the med tech companies had an increase in cost...they couldn't pass on to the hospitals...all of those comps now are behind us”
Source
Biggest. Bubble. In. Capital. Market. History | Mike Taylor 1-on-1 With Keith McCullough— HedgeyeCreated: 8/10/2026, 11:06:55 PM
My Notes
Loading notes...